According to CoinMeta, Chengda Biology announced that the company plans to make structural adjustments to 17 sub-projects under its "Human Vaccine Research and Development Project." Among these, 4 projects will be completed, 3 will be terminated, 1 will be temporarily suspended, 1 will change its implementation method, 1 will be merged and advanced, and 7 will continue to be pursued. The total planned investment of 837 million yuan remains unchanged. At the same time, the company intends to terminate the fundraising for the "Biotechnology Product Research and Development Production Base Project," with 138 million yuan remaining in the project's special account. The surplus funds will continue to be managed in this special account. This adjustment still needs to be approved by the company's shareholders' meeting.